Xinmei Shen

Xinmei Shen

Hong Kong
@shenxinmei
Reporter, Technology
Xinmei Shen joined the Post in 2017 and is a technology reporter. She covers content, entertainment, social media and internet culture. Previously, she was with the Post’s tech news site, Abacus. Before that, she was a reporting intern at The Information whilst studying at the University of Hong Kong.
Xinmei Shen joined the Post in 2017 and is a technology reporter. She covers content, entertainment, social media and internet culture. Previously, she was with the Post’s tech news site, Abacus. Before that, she was a reporting intern at The Information whilst studying at the University of Hong Kong.
Areas of Expertise:
China technology coverage, video production
Languages Spoken:
English, Mandarin

How Chinese biotech is graduating from licensing deals to broader partnerships

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
Advertisement

The US central bank raised rates for first time since 2023, Hong Kong followed and Goldman Sachs projects a sharp rise in Chinese firms’ global export share.

The flaw allowed for remote account takeovers without user interaction, prompting Tencent to patch the problem after Calif cybersecurity team flagged it.

videocam

The Chinese tech giant is going ‘full stack’, expanding beyond retail into chips, cloud and large language models as surging spending weighs on quarterly profits.

‘Neo-cloud’ provider Antimatter is helping businesses shift away from the US’ frontier AI models, promising lower costs and greater data sovereignty.

videocam
Related Topics
Biomedicine: Industry TrendsCancerChina technologyHong Kong stock marketBiomedicine: PolicyBanking & financeBiomedicine: CompaniesCryptocurrencyArtificial intelligence (AI)Z.ai